This session will focus on the mechanistic basis for the development of novel, non-CFTR directed small molecule therapies that may improve mucociliary clearance in CF.
Discuss the mechanistic basis of non-CFTR-mediated anion (Chloride and Bicarbonate) transport in the CF airway, and how small molecules directed at alternate anion transporters may bypass mutant CFTR in the CF airway.
Discuss the mechanistic basis of hypothesized defects in sodium transport in the CF airway, and how targeting this defect with small molecules may improve the pathophysiology of the CF airway.
Discuss the mechanistic basis of distorted mucociliary clearance in the CF airway in the context of how utilization of osmotic and mucolytic interventions may lead to improvements.
Note: Speaker Ronald Rubenstein's presentation was not recorded at his request.